New Therapy Cuts Heart Attack, Stroke Risk in High Cholesterol
- A recent international analysis suggests a new therapeutic approach could significantly lower the risk of heart attack, stroke, and cardiovascular mortality.
- The analysis indicates that initiating treatment with a combination of statins and ezetimibe immediately in patients at high cardiovascular risk is more effective than using statins alone.
- The research demonstrated that this new approach resulted in a 19% reduction in all-cause mortality and a 16% reduction in cardiovascular mortality. Furthermore, it lowered the risk of...
New Combination Therapy Shows Promise in Reducing Cardiovascular Risks
Table of Contents
- New Combination Therapy Shows Promise in Reducing Cardiovascular Risks
- new Combination Therapy: Your Questions Answered About Reducing Cardiovascular Risks
- What is the new combination therapy for cardiovascular risk?
- How does this combination therapy work?
- What are the key benefits of this new therapy?
- When should I start this combination therapy?
- What are the potential economic benefits of this treatment?
- Combination Therapy vs. Statin Therapy: A Comparison
A recent international analysis suggests a new therapeutic approach could significantly lower the risk of heart attack, stroke, and cardiovascular mortality.
The analysis indicates that initiating treatment with a combination of statins and ezetimibe immediately in patients at high cardiovascular risk is more effective than using statins alone. The study, published in Mayo Clinic Proceedings, examined data from 108,353 patients across 14 clinical studies, revealing a notable decrease in mortality and cardiovascular events.
Key Findings of the Study
The research demonstrated that this new approach resulted in a 19% reduction in all-cause mortality and a 16% reduction in cardiovascular mortality. Furthermore, it lowered the risk of heart attack and stroke by 18% and 17%, respectively, when compared to traditional high-dose statin therapy.
Researchers found that combining the two drugs led to a greater reduction in LDL cholesterol levels, achieving a 13 mg/dL reduction compared to statins alone. This improved the likelihood of reaching the target level of less than 70 mg/dL, with an 85% increase in the probability of success.
The study also emphasized the high tolerability of the combination therapy, noting a 44% lower risk of treatment suspension compared to high-dose statin therapy.
Optimal Timing for Therapy Initiation
The study raises the question of when to begin this therapy: immediately or after a two-month period of statin-only treatment? According to researchers,initiating the dual therapy immediately is the most effective strategy.
This strategy should become the new standard for patients at high risk. Waiting to evaluate the effectiveness of the only statins is frequently enough counterproductive and less effective to achieve the ideal levels of LDL cholesterol. It is an accessible solution, which does not require new expensive drugs, but which could reduce heart attacks, strokes and heart failures, with enormous benefits also economic for health systems.
Peter Toth, professor at the University of Illinois
new Combination Therapy: Your Questions Answered About Reducing Cardiovascular Risks
Cardiovascular disease remains a leading cause of death globally. Recent research has unveiled a promising new therapeutic approach that could significantly lower the risk of heart attacks, strokes, and overall cardiovascular mortality. This Q&A provides a comprehensive overview of this innovative treatment strategy.
What is the new combination therapy for cardiovascular risk?
the new therapeutic approach involves initiating treatment with a combination of statins and ezetimibe immediately for patients at high cardiovascular risk. This is a departure from the conventional approach of using statins alone.
How does this combination therapy work?
This combination therapy works by:
Lowering LDL Cholesterol: Combining statins and ezetimibe leads to a greater reduction in LDL cholesterol levels compared to statins alone. The study revealed a 13 mg/dL reduction in LDL cholesterol with the combination therapy.
Improving LDL cholesterol Target Achievement: The combination therapy increases the likelihood of reaching the target LDL cholesterol level of less than 70 mg/dL, with an 85% increase in the probability of success.
What are the key benefits of this new therapy?
The research highlights several key benefits:
Reduced Mortality: The combination therapy resulted in a 19% reduction in all-cause mortality and a 16% reduction in cardiovascular mortality.
Lowered Risk of Cardiovascular Events: The therapy reduced the risk of heart attack and stroke by 18% and 17%, respectively.
* High Tolerability: The combination therapy showed a 44% lower risk of treatment suspension compared to high-dose statin therapy.
When should I start this combination therapy?
According to researchers, initiating the dual therapy immediately is the most effective strategy. Peter Toth, a professor at the University of Illinois, suggests this strategy as a “new standard for patients at high risk.”
What are the potential economic benefits of this treatment?
Beyond the clinical benefits, the therapy offers potential economic advantages. Professor Toth highlights that this is “an accessible solution which could reduce heart attacks, strokes and heart failures with enormous benefits also economic for health systems.”
Combination Therapy vs. Statin Therapy: A Comparison
| Feature | Combination Therapy (Statin + Ezetimibe) | High-Dose Statin Therapy |
| :———————- | :————————————– | :———————– |
| All-Cause Mortality | 19% reduction | – |
| Cardiovascular Mortality | 16% reduction | – |
| Heart attack Risk | 18% reduction | – |
| Stroke Risk | 17% reduction | – |
| LDL Cholesterol Reduction | 13 mg/dL more | - |
| Treatment Suspension Risk | 44% Lower | – |